These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 12568397

  • 1. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
    Frith JC, Rogers MJ.
    J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
    [Abstract] [Full Text] [Related]

  • 2. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ.
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [Abstract] [Full Text] [Related]

  • 3. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 4. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
    Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ.
    Arthritis Rheum; 2001 Sep; 44(9):2201-10. PubMed ID: 11592386
    [Abstract] [Full Text] [Related]

  • 5. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.
    Frith JC, Mönkkönen J, Blackburn GM, Russell RG, Rogers MJ.
    J Bone Miner Res; 1997 Sep; 12(9):1358-67. PubMed ID: 9286751
    [Abstract] [Full Text] [Related]

  • 6. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.
    Sutherland KA, Rogers HL, Tosh D, Rogers MJ.
    Arthritis Res Ther; 2009 Sep; 11(2):R58. PubMed ID: 19405951
    [Abstract] [Full Text] [Related]

  • 7. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.
    Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE.
    Mol Pharmacol; 2002 May; 61(5):1255-62. PubMed ID: 11961144
    [Abstract] [Full Text] [Related]

  • 8. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite.
    Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, Mönkkönen J.
    Eur J Pharm Sci; 1999 May; 8(2):109-18. PubMed ID: 10210733
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ.
    Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
    Halasy-Nagy JM, Rodan GA, Reszka AA.
    Bone; 2001 Dec; 29(6):553-9. PubMed ID: 11728926
    [Abstract] [Full Text] [Related]

  • 18. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 19. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P.
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.